Open AccessV-ATPase as a mediator of treatment resistance in Glioblastoma Multiforme: an <em>in vitro</em> study to investigate new therapeutic strategies
Author(s) -
Eleonora Messuti,
Martina Giambra,
Serena Redaelli,
Andrea Di Cristofori,
Carlo Giussani,
Angela Bentivegna
Publication year - 2021
Publication title -
biomedical science and engineering
Language(s) - English
Resource type - Journals
ISSN - 2531-9892
DOI - 10.4081/bse.2021.182
Subject(s) - temozolomide , glioblastoma , bafilomycin , in vitro , cancer research , glioma , mediator , pharmacology , atpase , drug resistance , medicine , chemistry , biology , autophagy , enzyme , biochemistry , microbiology and biotechnology , apoptosis
Recent evidences suggest the involvement of the Vacuolar H+ ATPase (V-ATPase) in the development and/or progression of Glioblastoma Multiforme (GBM). This proton pump could be a valid therapeutic target but more in-depth studies are necessary. The aim of this study is to better define the in vitro effects on Glioma Stem Cell (GSC) primary cultures viability of single and combined treatment with Bafilomycin-A1 (Baf-A1), a V-ATPase inhibitor, and Temozolomide (TMZ), the chemotherapeutic agent currently used to treat GBM patients. We found out that GSC were resistant to TMZ and more sensitive to treatments with Baf-A1 and that the two drugs exerted a synergistic effect when administered together.